3.36  -0.04 (-1.18%)		04-15 16:00
Open: 3.41 High: 3.41 Volume: 21,632		Pre. Close: 3.4 Low: 3.32 Market Cap: 32(M)

Short term
Mid term
Targets	6-month :	3.98	1-year :	4.08
Resists	First :	3.4	Second :	3.5
Pivot price	3.4
Supports	First :	3.25	Second :	2.71
MAs	MA(5) :	3.39	MA(20) :	3.4
	MA(100) :	2.8	MA(250) :	2.69
MACD	MACD :	0	Signal :	0
%K %D	K(14,3) :	53.4	D(3) :	56.2
RSI	RSI(14): 51.2
52-week	High :	3.83	Low :	1.72

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ ACST ] has closed below the lower bollinger band by 4.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ ACST ] is to continue within current trading range. It is unclear right now based on current values. 86.2% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 25 bars. This is a sign that the market may be about to initiate a new trend.

If tomorrow:	Open lower	Open higher
High:	3.42 - 3.43	3.43 - 3.45
Low:	3.27 - 3.3	3.3 - 3.31
Close:	3.33 - 3.36	3.36 - 3.39

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

Thu, 11 Apr 2024
Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Down 78.8% in March - Defense World

Mon, 12 Feb 2024
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights - GlobeNewswire

Thu, 01 Feb 2024
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial - GlobeNewswire

Mon, 25 Dec 2023
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely? - Yahoo Finance

Tue, 14 Nov 2023
Will Acasti Pharma (NASDAQ:ACST) Spend Its Cash Wisely? - Simply Wall St

Mon, 10 Jul 2023
Acasti Announces WuXi Clinical as CRO to Conduct STRIVE-ON Pivotal Phase 3 Safety Trial for GTX-104 in aSAH ... - PR Newswire

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Neutral
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Shares Out	9 (M)
Shares Float	6 (M)
Held by Insiders	16 (%)
Held by Institutions	12.1 (%)
Shares Short	1 (K)
Shares Short P.Month	23 (K)

EPS	-5.68
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	6.88
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-8 %
Return on Equity (ttm)	-48.1 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.3
Qtrly Earnings Growth	0 %
Operating Cash Flow	-14 (M)
Levered Free Cash Flow	-8 (M)

PE Ratio	-0.6
PEG Ratio	0
Price to Book value	0.48
Price to Sales	0
Price to Cash Flow	-2.33

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.